Collaborations

Collaborations with Radboudumc

Radboudumc works with all kinds of healthcare providers, research institutes, organizations, companies and governments. We have highlighted a few of our greater strategic partnerships.

Contact

Mark van der Wolf

contact form

Academic partners

Maastricht UMC+ The Academic Alliance

Maastricht UMC+ and Radboudumc combined form the Academic Alliance. We bundle knowledge and expertise. *This page is currently under construction.*

Radboud University a significant impact

The shared commitment to a healthy society and sustainable healthcare forms the foundations for the strategic collaboration between Radboud University and Radboudumc.

to website

University of Twente TURBO program

Amongst other joint initiatives, Radboudumc and University of Twente facilitate the TURBO research program. to website

Healthcare partners

CWZ

This is first and foremost a healthcare collaboration, but also an important collaboration for education and research.

to website

Maasziekenhuis Pantein

This collaboration ensures that patients can easily be referred from one hospital to another. Sometimes the doctor "travels along" with the patient.

to website

Rijnstate

We have been collaborating with Rijnstate for years, in many different areas. In April 2023, we signed a strategic collaboration agreement to further expand on this.

to website

Sint Maartenskliniek

The Orthopedics, Rheumatology, Revalidation, Anaesthesiology, and Pharmacy departments are closely involved in this collaboration.

to website

Business partners

Terumo

Radboudumc en Terumo Europe NV work together on improving cancer treatments using holmium-166 microspheres. read more

Listen

Terumo

Radboudumc en Terumo Europe NV work together on improving cancer treatments using holmium-166 microspheres.

Holmium-166 microspheres are currently used in the image-guided irradiation of liver tumors from the inside. This technique is also called radioembolization or selective internal radiation therapy (SIRT). Using a catheter, millions of radioactive beads, or microspheres, are injected into a patient's hepatic artery. The radioactive microsphere then lodge in blood vessels in and around the targeted tumor(s), irradiating the tumor cells at close range.

The biggest challenge with radioembolization is getting the right number of microspheres to the right places in the body to reach the correct dose to the tumor. In Radboudumc’s MITeC operating rooms, it’s possible to follow the microspheres live on the MRI during treatment. This way it’s possible to learn to control them better and to adjust the dosage on the spot to the individual patient.

The holmium-166 microspheres are supplied by Deventer-based Quirem Medical, a Terumo Europe N.V. company. Quirem Medical and Radboudumc have been collaborating on radioembolization for several years. With the new collaboration agreement, Terumo is intensifying its research collaboration with Radboudumc.

Radioembolization is now mainly used in patients with primary or secondary liver cancer, for whom surgery is no longer an option. Radioembolization helps to extend the lives of these patients. Radboudumc and Terumo Europe N.V. hope to be able to offer them more perspectives in the future with this image-guided and personalized treatment.